ESMO 2023 | The role of liquid biopsy in brain cancers

Enrico Franceschi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, discusses the importance of obtaining liquid biopsies in patients with brain tumors. Liquid biopsy is fundamental in the treatment of many cancers for assessing individual cancer biology and treatment options, but this is more difficult in brain tumors due to the limited delivery of circulating tumor DNA (ctDNA) across the blood-brain barrier. Although cerebrospinal fluid is a more suitable prognostic assessment tool in these cancers, it is harder to obtain, meaning novel methods of accessing ctDNA and disrupting the blood-brain barrier are required. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.